Access the full text.
Sign up today, get DeepDyve free for 14 days.
E. Basic, M. Kappel, Arpit Misra, L. Sellner, B. Ratsch, D. Ostwald (2020)
Budget impact analysis of the use of oral and intravenous therapy regimens for the treatment of relapsed or refractory multiple myeloma in GermanyThe European Journal of Health Economics, 21
(2016)
Sherwood AM, inventors; United States Patent No.: US 9,371,558 B2: Compositions and method for measuring and calibrating amplification basin multiplexed PCR reactions. US patent application
Shaji Kumar, B. Paiva, K. Anderson, B. Durie, O. Landgren, P. Moreau, N. Munshi, S. Lonial, J. Bladé, M. Mateos, M. Dimopoulos, E. Kastritis, M. Boccadoro, M. Boccadoro, R. Orlowski, H. Goldschmidt, A. Spencer, J. Hou, W. Chng, S. Usmani, E. Zamagni, K. Shimizu, S. Jagannath, H. Johnsen, E. Terpos, A. Reiman, R. Kyle, P. Sonneveld, P. Richardson, P. McCarthy, H. Ludwig, Wenming Chen, M. Cavo, J. Harousseau, S. Lentzsch, J. Hillengass, A. Palumbo, A. Órfão, S. Rajkumar, J. Miguel, H. Avet-Loiseau (2016)
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.The Lancet. Oncology, 17 8
Entwurf einer Methodik für die Bewertung von Verhältnissen zwischen Nutzen und Kosten im System der deutschen gesetzlichen Krankenversicherung
(2017)
Measurable residual disease testing in multiple myeloma using an improved testing technology: population impact. A clinical and budget impact analysis
M. Hoechstetter, S. Nagel (2019)
Nichtkleinzelliges Lungenkarzinom (NSCLC)e.Curriculum Innere Medizin
H. Avet-Loiseau, H. Ludwig, O. Landgren, B. Paiva, C. Morris, Hui Yang, K. Zhou, S. Ro, M. Mateos (2019)
Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis.Clinical lymphoma, myeloma & leukemia
LEITLINIEN zur autologen Stammzelltransplantation von der Deutschen Arbeitsgemeinschaft für Knochenmarkund Blutstammzelltransplantation (DAG-KBT). Version 1, Stand
(2009)
AMNOG - Report 2020
Multiples Myelom . Leitlinie . Empfehlun - gen der Fachgesellschaft zur Diagnostik und Ther - apie hämatologischer und onkologischer Erkrankungen
L. Hörster, S. Neusser, Annika Trautner, Kathrin Pahmeier, H. Lax, A. Merkel-Jens, N. Lehmann, K. Jöckel, Julia Baum, U. Dührsen, J. Wasem, A. Neumann (2021)
Kosten der Nachsorge von Patienten mit hämatologischen NeoplasienGesundheitsökonomie & Qualitätsmanagement, 26
EPAR-Product information
O. Landgren, S. Devlin, Mathieu Boulad, S. Mailankody (2016)
Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysisBone marrow transplantation, 51
Tannosynt® flüssig (2012)
FACHINFORMATION (ZUSAMMENFASSUNG DER MERKMALE DES ARZNEIMITTELS)
KyprolisÒ 10 mg/30 mg/60 mg Pulver zur Herstellung einer Infusionslösung
Guideline on the use of minimal residual disease as a clinical endpoint in multiple myeloma studies. Draft
Lauer Taxe 4 . 0 . 2021
A. Attema, W. Brouwer, K. Claxton (2018)
Discounting in Economic EvaluationsPharmacoeconomics, 36
V. Wienert, H. Gerlach, G. Gallenkemper, B. Kahle, M. Marshall, E. Rabe, D. Stenger, M. Stücker, F. Waldermann, M. Zabel (2006)
LeitliniePhlebologie, 35
F. Davies (2017)
Is molecular remission the goal of multiple myeloma therapy?Hematology. American Society of Hematology. Education Program, 2017 1
(2020)
AMNOG-Report 2020. In: Storm A, editor. Beiträge zur Gesundheitsökonomie und Versorgungsforschung (Band 32)
(2018)
Minimal residual Oncol Ther disease negativity using deep sequencing is a major prognostic factor in multiple myeloma
(2021)
Minimal residual disease negativity does not overcome poor prognosis in high-risk multiple myeloma: a single-center retrospective study. Clin Lymphoma Myeloma Leuk
A. Perrot, V. Lauwers-Cances, J. Corre, N. Robillard, C. Hulin, M. Chrétien, T. Dejoie, S. Mahéo, A. Stoppa, B. Pégourié, L. Karlin, L. Garderet, B. Arnulf, C. Doyen, N. Meuleman, B. Royer, J. Eveillard, L. Benboubker, M. Dib, O. Decaux, A. Jaccard, K. Belhadj, S. Bréchignac, B. Kolb, C. Fohrer, M. Mohty, M. Macro, P. Richardson, V. Carlton, M. Moorhead, T. Willis, M. Faham, K. Anderson, J. Harousseau, X. Leleu, T. Facon, P. Moreau, M. Attal, H. Avet-Loiseau, N. Munshi (2018)
Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.Blood, 132 23
(2020)
Beiträge zur Gesundheitsökonomie und Versorgungsforschung (Band 32). Heidelberg: medhochzwei Verlag GmbH
M. Roussel, V. Lauwers-Cances, N. Robillard, C. Hulin, X. Leleu, L. Benboubker, G. Marit, P. Moreau, B. Pégourié, D. Caillot, C. Fruchart, A. Stoppa, C. Gentil, S. Wuillème, A. Huynh, B. Hébraud, J. Corre, M. Chrétien, T. Facon, H. Avet-Loiseau, M. Attal (2014)
Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélome.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 25
M. Attal, V. Lauwers-Cances, C. Hulin, X. Leleu, D. Caillot, M. Escoffre, B. Arnulf, M. Macro, K. Belhadj, L. Garderet, M. Roussel, C. Payen, C. Mathiot, J. Fermand, N. Meuleman, Sandrine Rollet, Michelle Maglio, Andrea Zeytoonjian, E. Weller, N. Munshi, K. Anderson, P. Richardson, T. Facon, H. Avet-Loiseau, J. Harousseau, P. Moreau (2017)
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for MyelomaThe New England Journal of Medicine, 376
(2021)
zur autologen Stammzelltransplantation von der Deutschen Arbeitsgemeinschaft für Knochenmark- und Blutstammzelltransplantation (DAG-KBT)
Adaptive Biotechnologies. clonoSEQÒ assay B-cell reagent set instructions for use
Chutima Kunacheewa, Hans Lee, K. Patel, Sheeba Thomas, B. Amini, S. Srour, Q. Bashir, Y. Nieto, M. Qazilbash, D. Weber, Lei Feng, R. Orlowski, P. Lin, E. Manasanch (2020)
Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma: A Single-Center Retrospective Study.Clinical lymphoma, myeloma & leukemia
(2020)
RKI). Krebs in Deutschland für 2015/2016
2021 vdek-Basisdaten des Gesundheitswesens in Deutschland
(2015)
inventors; United States Patent No.: US 9,150,905 B2: Compositions and method for measuring and calibrating amplification basin multiplexed Pcr reactions
(2016)
inventors; United States Patent No.: US 9,371,558 B2: Compositions and method for measuring and calibrating amplification basin multiplexed PCR reactions
N. Munshi, H. Avet-Loiseau, A. Rawstron, R. Owen, J. Child, A. Thakurta, P. Sherrington, M. Samur, A. Georgieva, K. Anderson, W. Gregory (2017)
Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysisJAMA Oncology, 3
(2015)
Sherwood AM, inventors; United States Patent No.: US 9,150,905 B2: Compositions and method for measuring and calibrating amplification basin multiplexed Pcr reactions. US patent application
(2015)
Krebs in Deutschland für
(2018)
Minimal residual 618 Oncol Ther (2021) 9:607–619 disease negativity using deep sequencing is a major prognostic factor in multiple myeloma
A. Briggs, M. Sculpher (1998)
An Introduction to Markov Modelling for Economic EvaluationPharmacoEconomics, 13
(2018)
Discounting in economic evaluations. Pharmacoeconomics
IntroductionThe measurement of minimal residual disease (MRD) with clonoSEQ® can be used in the assessment of B-cell lymphoid tumor burden throughout treatment with accuracy, sensitivity and standardization when compared to traditional cytomorphology. With the approval of novel treatments, standardized MRD assessment with improved performance is increasingly important. The aim of this analysis is to estimate the cost-effectiveness of MRD testing with clonoSEQ® compared to no MRD testing for patients with multiple myeloma (MM) on maintenance therapy in Germany.MethodsThe cost impact of clonoSEQ® was analyzed from the German statutory insurance perspective. Clinical data were derived from the literature and expert opinions. Cost input was utilized based on publicly available data and literature. Patients in the MRD arm were tested every 6 months. The deterministic Markov model consists of six health states, and every patient begins at the start of maintenance. Included therapies are lenalidomide for maintenance and carfilzomib, lenalidomide and dexamethasone for relapse.ResultsFor a time horizon of 10 years, the deterministic cost impact analysis shows total cost of €279,483 for patients using clonoSEQ® in comparison to €356,623 for simulated patients without MRD testing. The main drivers of the cost differences are saved cost of drug holiday. The savings per patient in 1 year are €18,396. Savings after 3 years are €69,991 per patient. Savings after 10 years are €77,140 per patient.ConclusionsBased on the underlying model, clonoSEQ® can support German health insurance funds to use high-cost drugs more efficiently in the treatment of myeloma.
Oncology and Therapy – Springer Journals
Published: Dec 1, 2021
Keywords: Economic analysis; Minimal residual disease; MRD; Multiple myeloma; German statutory insurance
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.